Azienda Ospedaliero Universitaria Policlinico Vittorio Emanuele

Catania 95125

0 studies enrolling now · 13 studies all time

What they study most

Bullous Pemphigoid, Cystic Fibrosis, Idiopathic Pulmonary Fibrosis, Leukemia, Locally Recurrent Breast Cancer, Metastatic Breast Cancer, Multiple Myeloma, Myeloid Leukemia, Chronic, Chronic Phase, Non-Small Cell Lung Cancer, Post-Essential Thrombocythemia MF (Post-ET-MF), Post-Polycythemia Vera MF (Post-PV-MF), Post-stroke Spasticity

Studies at this site

• Ponatinib in Participants With Resistant Chronic Phase Chronic Myeloid Leukemia (CP-CML) to Characterize the Efficacy and Safety of a Range of Doses — Completed
• A Phase 3 Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid — Stopped early
• Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1) — Running, not enrolling
• A Study of Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple Myeloma — Stopped early
• A Study to Investigate Leramistat in Patients With IPF — Withdrawn before enrolling
• An Observational Study of Presentation, Treatment Patterns, and Outcomes in Multiple Myeloma Participants — Stopped early
• Pivotal Study in HER2 Negative, Locally Recurrent or Metastatic Breast Cancer — Stopped early
• KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treatment — Status unconfirmed
• Dysport® Adult Lower Limb Spasticity Follow-on Study — Completed
• A Double-blind Study of Paclitaxel in Combination With Reparixin or Placebo for Metastatic Triple-Negative Breast Cancer — Completed
• Study of Aztreonam for Inhalation in Children With Cystic Fibrosis and New Infection of the Airways by Pseudomonas Aeruginosa Bacteria — Stopped early
• An Investigational Immuno-therapy Study of Ulocuplumab in Combination With Low Dose Cytarabine in Patients With Newly Diagnosed Acute Myeloid Leukemia — Stopped early
• Efficacy and Safety Study of Ozanimod in Relapsing Multiple Sclerosis — Completed